Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JLP-1401 vs Co-administered Telmisartan/Amlodipine and Rosuvastatin
NCT03707899Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, amlodipine and rosuvastatin in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Dec 2018; status: completed.
02
Drugs
telmisartanamlodipinerosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03707899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707899.